House Dust Mite Allergy - Pipeline Insight, 2024

This “House Dust Mite Allergy - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in House Dust Mite Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

House Dust Mite Allergy Understanding

House Dust Mite Allergy: Overview

Dust mite allergy is an allergic condition that occurs as a reaction to the dust mite allergens that commonly live in household dust. It is also known as house dust allergy. It is sensitization and an allergic reaction to the droppings of the dust mites. The droppings are an indoor aeroallergen, which on inhalation triggers the allergic reaction. The prevalence of atopic diseases like allergic rhinitis and asthma with house dust mite being the allergen has been increasing. House dust allergy was first identified as an allergen around 1920. In 1967, Voorhorst et al. identified Dermatophagoides pteronyssinus as the causative allergen for house dust allergy. The first mite allergen identified was the cysteine protease Dermatophagoides pteronyssinus allergen I, or Der p 1 in 1980, followed by Der p 2, and homologous Dermatophagoides farinae 1 and 2. The house dust mite (HDM or DM) is a predominant source of indoor aeroallergens. Some of the allergic diseases that have been associated with the HDM are allergic rhinoconjunctivitis, allergic asthma, and atopic eczema. The best treatment strategy for allergic rhinitis consists of allergen avoidance first, in junction with pharmacotherapy and allergen immunotherapy (AIT). The appropriate pharmacotherapy consists of antihistamines, leukotriene receptor antagonists, and inhaled or intranasal corticosteroids (ICS). All these treatments are effective and safe, but unfortunately, haven't proved to change the course of HDM related allergic diseases.

House Dust Mite Allergy - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the House Dust Mite Allergy pipeline landscape is provided which includes the disease overview and House Dust Mite Allergy treatment guidelines. The assessment part of the report embraces, in depth House Dust Mite Allergy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, House Dust Mite Allergy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for House Dust Mite Allergy.
• In the coming years, the House Dust Mite Allergy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics that are working to assess challenges and seek opportunities that could influence House Dust Mite Allergy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• A detailed portfolio of major pharma players who are involved in fueling the House Dust Mite Allergy treatment market. Several potential therapies for House Dust Mite Allergy are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the House Dust Mite Allergy market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of House Dust Mite Allergy) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

House Dust Mite Allergy Emerging Drugs Chapters

This segment of the House Dust Mite Allergy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

House Dust Mite Allergy Emerging Drugs

Tregalizumab: T-Balance Therapeutics Tregalizumab selectively activates the immunomodulatory subpopulation of T cells called regulatory T cells or Tregs. Tregs are essential for maintaining peripheral immune tolerance; they suppress autoreactive T cells (i.e. cells targeted against the body’s own structures) and thereby prevent the excessive activation of T lymphocytes seen in autoimmune and inflammatory diseases. Tregalizumab acts early in the inflammatory cascade, providing the opportunity for a novel therapeutic approach aimed at the prevention and treatment of inflammatory conditions.

FP-025: Foresee Pharmaceuticals FP-025 is a highly selective (non-hydroxamate), oral non-competitive small molecule inhibitors of Matrix Metalloproteinase-12/Macrophage elastase (MMP-12), an enzyme that acts as a key mediator of matrix degradation and remodeling in both normal development and maintenance. FP-025 is well tolerated in healthy human volunteers and allergic asthmatic patients upon single and repeat dosing, and exhibits good single and multiple dose oral pharmacokinetics.

House Dust Mite Allergy: Therapeutic Assessment

This segment of the report provides insights about the different House Dust Mite Allergy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in House Dust Mite Allergy

There are approx. 5+ key companies which are developing the therapies for House Dust Mite Allergy. The companies which have their House Dust Mite Allergy drug candidates in the most advanced stage, i.e. phase II include, T-Balance Therapeutics.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

House Dust Mite Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

House Dust Mite Allergy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses House Dust Mite Allergy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging House Dust Mite Allergy drugs.

House Dust Mite Allergy Report Insights

• House Dust Mite Allergy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

House Dust Mite Allergy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing House Dust Mite Allergy drugs?
• How many House Dust Mite Allergy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of House Dust Mite Allergy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the House Dust Mite Allergy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for House Dust Mite Allergy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• T-Balance Therapeutics
• Worg Pharmaceuticals
• Advagene Biopharma Co., Ltd.
• Immunotek SL
• Tolerogenics S.à.r.l.
• Foresee Pharmaceuticals

Key Products

• Tregalizumab
• WP1049
• Airway Allergy Immunotherapy
• MM09-MG01
• FP-025

This product will be delivered within 2 business days.